Company Description

ImmunoBlue harnesses the advantages of nanomedicine and immunotherapy for treating brain malignancies and other solid tumors. The company has developed a T cell expansion platform that utilizes an FDA-approved nanoparticle, which generates potent responses from the immune system when activated with a laser. These effects mediate the expansion of personalized and multi-targeted tumor-specific T cells in an antigen-agnostic manner, for use in autologous adoptive T cell therapy to treat cancer.